GTXI News a biopharmaceutical company dedicated to the discovery,
development and commercialization of therapeutics primarily related to the
treatment of serious mens health conditions, announced today that it has
entered into a collaboration with Tessera, Inc. Under the terms of the
agreement GTx will provide clinical samples from its completed Phase IIb
clinical trial program which evaluated ACAPODENETM toremifene citrate for
the reduction of the incidence of prostate cancer in men with high grade
prostatic intraepithelial neoplasia PIN, a premalignant lesion that has the
potential to progress to prostate cancer.

Original Article: GTx, Inc. Collaborates with Tessera, Inc. to Develop a Diagnostic Test to Detect High Grade PIN

Notice: The preceding article was not written by a member of the Anti-Aging Revolution. This article is provided for informational and reference purposes only. The Anti-Aging Revolution cannot guarantee the stability of third-party outside links.